Glycomimetics Inc (GLYC)
$0.16
Performance
- $0.16$0.17$0.16
3.13%
Downside
Day's Volatility :8.5%
Upside
5.55%
- $0.16$3.53$0.16
3.13%
Downside
52 Weeks Volatility :95.61%
Upside
95.47%
Returns
| Period | Glycomimetics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -38.97% | 0.0% |
6 Months | -94.39% | 0.0% |
1 Year | -89.46% | 0.0% |
3 Years | -93.02% | -22.3% |
Highlights
Market Capitalization | 10.7M |
Book Value | $0.31 |
Earnings Per Share (EPS) | -0.6 |
PEG Ratio | 0.0 |
Wall Street Target Price | 0.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -408770.5% |
Return On Assets TTM | -59.25% |
Return On Equity TTM | -104.49% |
Revenue TTM | 10.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 75.0K |
EBITDA | -40.8M |
Diluted Eps TTM | -0.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.61 |
EPS Estimate Next Year | -0.43 |
EPS Estimate Current Quarter | -0.17 |
EPS Estimate Next Quarter | -0.16 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 368.75%
Technicals Summary
Sell
Neutral
Buy
Glycomimetics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Glycomimetics Inc | -9.92% | -94.39% | -89.46% | -93.02% | -95.73% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Glycomimetics Inc | NA | NA | 0.0 | -0.61 | -1.04 | -0.59 | NA | 0.31 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Glycomimetics Inc | Buy | $10.7M | -95.73% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Glycomimetics Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 126.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 162.2%
Institutional Holdings
Bvf Inc
14.80%Artal Group S A
13.32%Octagon Capital Advisors LP
4.65%Vanguard Group Inc
4.18%AXA SA
2.46%Goldman Sachs Group Inc
1.25%
Company Information
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
Organization | Glycomimetics Inc |
Employees | 35 |
CEO | Mr. Harout Semerjian |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$0.16
-4.56%
Keyarch Acquisition Corp
$0.16
-4.56%
Connexa Sports Technologies Inc
$0.16
-4.56%
Us Value Etf
$0.16
-4.56%
First Wave Biopharma Inc
$0.16
-4.56%
Global X Msci Next Emerging
$0.16
-4.56%
Fat Projects Acquisition Corp
$0.16
-4.56%
Capital Link Global Fintech
$0.16
-4.56%
Applied Uv Inc
$0.16
-4.56%